Ardelyx chief patient officer sells $41,419 in stock
What it means
- What to watch: There is a hard number in this story ($41,419) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $ARDX +1.49% in the latest session.
- Timing: It landed while New York slept, so the session change beside it belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
$ARDX last traded at $3.08, +1.49% on the session. That puts it 63% shy of its 52-week high of $8.40 and 4.1% clear of its low of $2.96 — within a tenth of its 52-week low. Over the year it has ranged 184% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $ARDX page.
How much coverage it is getting
This is the only story Wook has logged on $ARDX in the last 30 days — a quiet name that just got a headline. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$ARDX earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $ARDX page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ARDX is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ARDX. It carried $41,419, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 26, 2026. $ARDX has moved -19.71% ($3.83 to $3.08). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.